1. The role of neuraminidase in TLR4‐MAPK signalling and the release of cytokines by lupus serum‐stimulated mesangial cells
- Author
-
Tamara K. Nowling, Bethany J. Wolf, Jessalyn Rodgers, Kamala P. Sundararaj, and Peggi M. Angel
- Subjects
Male ,Serum ,0301 basic medicine ,Mice, Inbred MRL lpr ,medicine.medical_specialty ,p38 mitogen-activated protein kinases ,Immunology ,Lupus nephritis ,Neuraminidase ,Inflammation ,Kidney ,Mice ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Internal medicine ,medicine ,Animals ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Extracellular Signal-Regulated MAP Kinases ,skin and connective tissue diseases ,Interleukin 6 ,Receptor ,Cells, Cultured ,Systemic lupus erythematosus ,biology ,Mesangial cell ,Chemistry ,Original Articles ,medicine.disease ,Lupus Nephritis ,Mice, Inbred C57BL ,Toll-Like Receptor 4 ,030104 developmental biology ,Endocrinology ,Gene Expression Regulation ,Mesangial Cells ,TLR4 ,biology.protein ,Cytokines ,Female ,medicine.symptom ,Signal Transduction ,030215 immunology - Abstract
Previously, we demonstrated neuraminidase (NEU) activity or NEU1 expression, specifically, is increased in the kidneys of lupus mice and urine of human patients with nephritis. Additionally, NEU activity mediates IL-6 secretion from lupus-prone MRL/lpr primary mouse mesangial cells (MCs) in response to an IgG mimic. IL-6 mediates glomerular inflammation and promotes tissue damage in patients and mouse strains with lupus nephritis. This study further elucidates the mechanisms by which NEU activity and NEU1 specifically mediates the release of IL-6 and other cytokines from lupus-prone MCs. We demonstrate significantly increased release of multiple cytokines and NEU activity in MRL/lpr MCs in response to serum from MRL/lpr mice (lupus serum). Inhibiting NEU activity significantly reduced secretion of three of those cytokines: IL-6, GM-CSF and MIP1α. Message levels of Il-6 and Gm-csf were also increased in response to lupus serum and reduced when NEU activity was inhibited. Neutralizing antibodies to cell-surface receptors and MAPK inhibitors in lupus serum- or LPS-stimulated MCs indicate TLR4 and p38 or ERK MAP kinase signalling play key roles in the NEU-mediated secretion of IL-6. Significantly reduced IL-6 release was observed in C57BL/6 (B6) Neu1+/+ primary MCs compared with wild-type (Neu1+/+) B6 MCs in response to lupus serum. Additional results show inhibiting NEU activity significantly increases sialic acid-containing N-glycan levels. Together, our novel observations support a role for NEU activity, and specifically NEU1, in mediating release of IL-6 from lupus-prone MCs in response to lupus serum through a TLR4-p38/ERK MAPK signalling pathway that likely includes desialylation of glycoproteins.
- Published
- 2021
- Full Text
- View/download PDF